Soligenix, July 18th

Christopher J. Schaber, PhD
Chairman, President and Chief Executive Officer

Christopher J. Schaber has over 29 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been our President and Chief Executive Officer and a director since August 2006. He was appointed Chairman of the Board on October 8, 2009. He also serves on the board of directors of the Biotechnology Council of New Jersey (“BioNJ”) since January 2009 and the Alliance for Biosecurity since October 2014, and has been a member of the corporate councils of both the National Organization for Rare Diseases (“NORD”) and the American Society for Blood and Marrow Transplantation (“ASBMT”) since October 2009 and July 2009, respectively. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, pre-clinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA degree from Western Maryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his PhD degree in Pharmaceutical Sciences from the Union Graduate School.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company has two pivotal Phase 3 trials underway, as well as a pipeline of vaccine/biodefense programs that are funded by third parties.

The Company has upcoming important catalysts in their rare disease pipeline. Two Phase 3 clinical trials in cutaneous T-cell lymphoma (CTCL) and oral mucositis. Important data reads are now very close, occurring throughout 2019 and early 2020, which include:

The first … an interim efficacy analysis for oral mucositis expected in September 2019;
The second … top-line final results for CTCL expected in 1Q 2020; and
The third … top-line final results for oral mucositis currently expected in 1H 2020, depending on the outcome of the interim analysis

Investment Highlights:

• Multiple products with fast track and/or orphan designation, each of which holds potential for significant commercial returns
• Three Phase 3 assets, two with data readout approaching
  • Cutaneous T-cell lymphoma (SGX301) – Pivotal study in progress; interim analysis complete; final results 1Q 2020
  • Oral mucositis in head & neck cancer (SGX942) – Pivotal study in progress; interim analysis 3Q 2019; final results 1H 2020
  • Pediatric Crohn’s disease (SGX203) – Pivotal study initiation contingent upon additional funding and/or partnership
• Steady stream of material news to generate attention and build value
• Collaborations with biotech, academia and government agencies
• Non-dilutive government funding helps cover operating expenses
  • NIH grant awards of ~$3.0M total for both SGX301 and SGX942 pivotal studies
  • NIH contract award of up to $24.7M supporting the development of RiVax® for pre-exposure to ricin toxin
    • Potential to receive biodefense priority review voucher with US FDA approval

Key Statistics: June 2019

• Ticker: SNGX
• Price: $0.67
• Market cap: ~$12.2mm
• Average volume: 110,172
• 52 Week Range: $0.65 – $2.2
• Shares Outstanding: 18.19mm
• Public Float: ~14,19mm shares
• Cash: ~$7.2mm
• Institutional Buyers: Knoll Capital Management, The Vanguard Group, Susquehanna International Group, Citadel Advisors
• Analyst Coverage: James Molloy – Alliance Global Partners, Jason McCarthy, PhD – Maxim Group, David Bautz, PhD – Zack’s Investment Research, Inc.